These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 23253216)

  • 1. A vaccine in renal cell carcinoma: are we nearing reality?
    Bedke J; Gouttefangeas C; Kruck S; Stenzl A
    Expert Rev Anticancer Ther; 2012 Dec; 12(12):1503-5. PubMed ID: 23253216
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccines for colorectal cancer and renal cell carcinoma.
    Kabaker K; Shell K; Kaufman HL
    Cancer J; 2011; 17(5):283-93. PubMed ID: 21952277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous renal cell cancer vaccines using heat shock protein-peptide complexes.
    Aalamian M; Fuchs E; Gupta R; Levey DL
    Urol Oncol; 2006; 24(5):425-33. PubMed ID: 16962495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse of renal cell carcinoma with disappearance of HLA class I following hTERT peptide vaccination.
    Yasukawa M; Ochi T; Fujiwara H
    Ann Oncol; 2010 Oct; 21(10):2122-2124. PubMed ID: 20860992
    [No Abstract]   [Full Text] [Related]  

  • 5. TroVax(®) vaccine therapy for renal cell carcinoma.
    Zhang RT; Bines SD; Ruby C; Kaufman HL
    Immunotherapy; 2012 Jan; 4(1):27-42. PubMed ID: 22149999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines in renal cell carcinoma.
    Kübler H; Vieweg J
    Semin Oncol; 2006 Oct; 33(5):614-24. PubMed ID: 17045091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell fusion technology vaccine tested in kidney cancer clinical trial.
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):620. PubMed ID: 12503204
    [No Abstract]   [Full Text] [Related]  

  • 8. Tailor-made renal cell carcinoma vaccines.
    Dranoff G
    Cancer Cell; 2012 Sep; 22(3):287-9. PubMed ID: 22975372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific antitumour vaccine for renal cancer.
    Fishman M; Antonia S
    Lancet; 2004 Feb; 363(9409):583-4. PubMed ID: 14987879
    [No Abstract]   [Full Text] [Related]  

  • 10. Ex vivo gene therapy using granulocyte-macrophage colony-stimulating factor-transduced tumor vaccines.
    Kawai K; Tani K; Asano S; Akaza H
    Mol Urol; 2000; 4(2):43-6. PubMed ID: 12006240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioactivity of human GM-CSF gene therapy in metastatic renal cell carcinoma and prostate cancer.
    Simons JW
    Hinyokika Kiyo; 1997 Nov; 43(11):821-2. PubMed ID: 9436029
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma.
    Berntsen A; Geertsen PF; Svane IM
    Eur Urol; 2006 Jul; 50(1):34-43. PubMed ID: 16675096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring immune therapy for renal cancer.
    Matsushita H; Kakimi K; Tomita Y; Tatsugami K; Naito S; Suekane S; Noguchi M; Moriya F; Matsuoka K; Itoh K; Kobayashi H; Eto M; Takahashi W; Kawano Y; Wada Y
    Int J Urol; 2011 Jun; 18(6):412-21. PubMed ID: 21599759
    [No Abstract]   [Full Text] [Related]  

  • 14. Dendritic cells for the treatment of metastatic renal cell carcinoma: at a low ebb?
    Patard JJ
    Eur Urol; 2006 Jul; 50(1):11-3. PubMed ID: 16713068
    [No Abstract]   [Full Text] [Related]  

  • 15. 5T4 as a target for immunotherapy in renal cell carcinoma.
    Elkord E; Shablak A; Stern PL; Hawkins RE
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1705-9. PubMed ID: 19954280
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunotherapeutic approaches for renal cancer.
    Pizza G; de Vinci C; Viza D
    Folia Biol (Praha); 2002; 48(5):167-81. PubMed ID: 12448765
    [No Abstract]   [Full Text] [Related]  

  • 17. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
    Acres B
    J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.
    Fishman M; Hunter TB; Soliman H; Thompson P; Dunn M; Smilee R; Farmelo MJ; Noyes DR; Mahany JJ; Lee JH; Cantor A; Messina J; Seigne J; Pow-Sang J; Janssen W; Antonia SJ
    J Immunother; 2008 Jan; 31(1):72-80. PubMed ID: 18157014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current immunotherapeutic strategies in renal cell carcinoma.
    Amato RJ
    Surg Oncol Clin N Am; 2007 Oct; 16(4):975-86, xi-xii. PubMed ID: 18022554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for renal cell cancer.
    Yang JC; Childs R
    J Clin Oncol; 2006 Dec; 24(35):5576-83. PubMed ID: 17158543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.